Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Research Progress of FLT3 Mutation in Acute Myeloid Leukemia --Review].

Zhongguo shi yan xue ye xue za zhi - 1 Jun 2023

Guo Lu, Xiong Hui-Xia

Abstract excerpt

Acute myeloid leukemia (AML) is a heterogeneous hematopoietic tumor originated from hematopoietic stem cells. FLT3 is an important receptor tyrosine kinase in cell signal transduction pathway and one of the common mutated genes in AML. AML patients with FLT3-ITD mutation have a poor prognosis and tendency to relapse. Therefore, early identification of FLT3 gene mutation and selection of appropriate treatment are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to fms-Like Tyrosine Kinase 3
Share to Leukemia, Myeloid, Acute
Share to Mutation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Protein Kinase Inhibitors

Share to Receptor Protein-Tyrosine Kinases

Share to Signal Transduction

Source

Identifiers

PMID: 37356962
DOI: 10.19746/j.cnki.issn.1009-2137.2023.03.046

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Research Progress of FLT3 Mutation in Acute Myeloid Leukemia --Review].PMID 37356962Read ↗

Advances in clinical studies of FLT3 inhibitors in acute myeloid leukemia.Semantic proximity Read ↗

Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemiaSemantic proximity Read ↗

FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor developmentSemantic proximity Read ↗

[Current status and challenges of AML treatment with FLT3 inhibitors].Semantic proximity Read ↗

[Pathogenesis and treatment of acute myeloid leukemia with FLT3 mutations].Semantic proximity Read ↗

Advances in the pathogenesis of FLT3 -mutated acute myeloid leukemia and targeted treatments.Semantic proximity Read ↗

[Ⅱ. Recent Advances and Problems of FLT3 Inhibitor in AML Treatment].Semantic proximity Read ↗

Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy.Semantic proximity Read ↗

FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance.Semantic proximity Read ↗

FLT3 inhibitors: clinical potential in acute myeloid leukemiaSemantic proximity Read ↗

Targeting FLT3 Mutations in Acute Myeloid LeukemiaSemantic proximity Read ↗

Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel ApproachesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.